AW
ACRV icon

Avion Wealth’s Acrivon Therapeutics ACRV Stock Holding History

Avion Wealth’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-88
Closed – – 1110
2025
Q1 		$0 Buy
+88
New +$474 ﹤0.01% 974
2024
Q4 		– Sell
-88
Closed – – 971
2024
Q3 		$0 Hold
88
– – ﹤0.01% 958
2024
Q2 		$0 Hold
88
– – ﹤0.01% 865
2024
Q1 		$1K Buy
+88
New +$408 ﹤0.01% 823

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Avion Wealth's ACRV Position: Q2 2025 in Review

Avion Wealth sold out of Acrivon Therapeutics (ACRV) in Q2 2025, closing a stake of 88 shares.

Avion Wealth first reported a position in ACRV in Q1 2024 and held it in 4 quarters. The position peaked at $1K in Q1 2024. 53 funds tracked by Wall St. Rank hold ACRV as of Q2 2025.

  • Avion Wealth reported no remaining Acrivon Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Avion Wealth sold 88 Acrivon Therapeutics shares in Q2 2025.
  • Avion Wealth first reported a position in Acrivon Therapeutics in Q1 2024 and held it in 4 quarters.
  • Avion Wealth's Acrivon Therapeutics position peaked at $1K in Q1 2024.
  • 53 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2025.

Based on Avion Wealth's 13F filing for Q2 2025, filed 25 Jul 2025.